Eton Pharmaceuticals, Inc.
Financials
Valuation Metrics
Eton Pharmaceuticals, Inc.'s Market Cap is $1.59B. At end of 2025 it was $455M. Ranked #2174 of 3,121 in US market (top 70%), #858 of 1,463 on NASDAQ (top 59%), #158 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 59%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.59B | US#2,174/3,121 Sec#158/266 |
| Revenue | $106M | US#2,691/3,121 Sec#123/266 |
| Net Income | $13M | US#2,149/3,121 Sec#69/266 |
| Total Assets | $116M | US#3,054/3,121 Sec#261/266 |
| Net Assets | $47M | US#2,871/3,121 Sec#226/266 |
| Employees | 44 | US#2,726/3,121 Sec#214/266 |
| Value | ||
| P/E | 125.03x | US#2,137/3,121 Sec#69/266 |
| P/B | 34.05x | US#2,866/3,121 Sec#232/266 |
| P/S | 15.02x | US#2,798/3,121 Sec#134/266 |
| EV/EBITDA | 85.57x | US#2,428/3,121 Sec#77/266 |
| FCF Yield | 0.93% | US#2,196/3,121 Sec#77/266 |
| Profitability | ||
| ROE | 27.24% | US#347/3,121 Sec#19/266 |
| ROA | 10.96% | US#414/3,121 Sec#30/266 |
| Op. Margin | 15.44% | US#1,184/3,121 Sec#49/266 |
| Revenue Growth | 81.49% | US#127/3,121 Sec#37/266 |
| Financial Health | ||
| Debt Ratio | 148.59% | US#1,492/3,121 Sec#189/266 |
| Total Debt | $29M | US#2,703/3,121 Sec#179/266 |
| FCF | $15M | US#2,213/3,121 Sec#79/266 |
| Cash | $27M | US#2,792/3,121 Sec#250/266 |
| Current Ratio | 1.52x | US#1,651/3,121 Sec#239/266 |
| Net Debt/EBITDA | 0.12x | US#629/3,121 Sec#37/266 |
| Performance | ||
| 1Y Return | 200.65% | US#54/3,121 Sec#22/266 |
| 1M Return | -9.73% | US#2,436/3,121 Sec#185/266 |
| From 52W High | -16.38% | US#1,045/3,121 Sec#73/266 |
| 1Y MDD | -36.17% | US#1,808/3,121 Sec#123/266 |
| Trading | ||
| Volume | 569,812 shares | US#2,498/3,121 Sec#243/266 |
| Trading Value | $32M | US#2,102/3,121 Sec#166/266 |
| Per Share | ||
| EPS | $0.44 | US#1,909/3,121 Sec#60/266 |
| BPS | $1.63 | US#2,617/3,121 Sec#187/266 |
Company Info
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.